EyePoint Pharmaceuticals to Showcase at Upcoming Conferences
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company dedicated to developing groundbreaking therapeutics for serious retinal diseases, has announced its management's participation in several upcoming investor conferences. These events provide a platform for the company to engage with potential investors and stakeholders about its innovative pipeline.
Details of Upcoming Conferences
Guggenheim's Inaugural Healthcare Innovation Conference
This conference will feature a fireside chat with EyePoint's management on Monday at 2:00 p.m. ET. It represents a significant opportunity for the company to discuss its advancements and future prospects.
UBS Global Healthcare Conference
Scheduled for Wednesday at 1:15 p.m. PT, this event will also include a fireside chat, allowing the company to connect meaningfully with healthcare investors and analysts.
Jefferies London Healthcare Conference
This corporate presentation will take place on Tuesday at 8:00 a.m. GMT, where EyePoint will provide insights into its innovative drug delivery technologies and future clinical trials.
BTIG 4th Annual Ophthalmology Day
On Monday at 10:00 a.m. ET, management will participate in a fireside chat, further highlighting the company's commitment to advancing its therapeutic options.
EyePoint's Innovative Pipeline
EyePoint Pharmaceuticals utilizes its proprietary Durasert E™ technology to enhance intraocular drug delivery. The lead product, DURAVYU™ (previously known as EYP-1901), is currently undergoing pivotal Phase 3 clinical trials targeting wet age-related macular degeneration (AMD) and a Phase 2 trial for diabetic macular edema (DME). These conditions profoundly impact the vision of individuals over 50 years old, and EyePoint is focused on delivering effective treatment options.
Progress and Expectations
EyePoint anticipates topline data from its Phase 2 trial for DME in the first quarter of 2025. Additionally, topline results from the Phase 3 trials for wet AMD are expected in 2026. This timeline marks a crucial milestone for the company as it prepares to make significant contributions to ophthalmic treatments.
The Technology Behind EyePoint
The Durasert® technology has been validated through multiple FDA-approved products and has shown a favorable safety profile across thousands of administrations in patients. This established technology positions EyePoint well within the biopharmaceutical landscape.
About EyePoint Pharmaceuticals
Headquartered in Watertown, Massachusetts, EyePoint Pharmaceuticals is a clinical-stage biopharmaceutical company committed to developing therapies that improve patients' lives. The company is innovative in its approach and aims to address significant unmet needs in treating severe retinal diseases.
Company Contact Information
For further inquiries, please contact:
Investors:
Christina Tartaglia
Precision AQ (formerly Stern IR)
Direct: 212-698-8700
Email: christina.tartaglia@precisionaq.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
Email: aphillips@greenroompr.com
Frequently Asked Questions
What is the significance of EyePoint's participation in these conferences?
EyePoint's participation in these conferences allows the company to engage with potential investors and share insights on its innovative therapies.
What is DURAVYU™?
DURAVYU™ (formerly EYP-1901) is an investigational therapeutic designed for sustained delivery in treating VEGF-mediated retinal diseases.
What clinical trials is EyePoint currently conducting?
EyePoint is conducting Phase 3 trials for wet AMD and Phase 2 trials for DME, both critical conditions affecting vision.
Where is EyePoint Pharmaceuticals located?
EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
How can investors learn more about EyePoint's upcoming presentations?
Investors can access the webcast and archived replays of the presentations through the Investors section of the company website.